

RIGEL PHARMACEUTICALS INC  
Form 8-K  
March 08, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 7, 2016**

**RIGEL PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-29889**  
(Commission File No.)

**94-3248524**  
(IRS Employer Identification No.)

**1180 Veterans Boulevard**

**South San Francisco, CA 94080**

(Address of principal executive offices)

Edgar Filing: RIGEL PHARMACEUTICALS INC - Form 8-K

94080

(Zip Code)

Registrant's telephone number, including area code: **(650) 624-1100**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b)

On March 8, 2016, Rigel Pharmaceuticals, Inc. (the Company) announced the appointment of Anne-Marie Duliege, M.D., M.S. to the role of Chief Medical Officer of the Company. Dr. Duliege succeeds Elliot Grossbard, M.D., who has served with Company in numerous positions over the last 14 years, most recently as Chief Medical Officer. In connection with Dr. Duliege's appointment as Chief Medical Officer, on March 7, 2016, Dr. Grossbard retired from that position, and will remain with the Company, advising on the new drug application filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura.

A copy of the Company's press release, titled "Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer," is furnished as Exhibit 99.1 hereto and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1 Press release, dated March 8, 2016, titled "Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer."

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 8, 2016

**RIGEL PHARMACEUTICALS, INC.**

By:

/s/ Dolly A. Vance

Dolly A. Vance

*Executive Vice President, General Counsel and Corporate Secretary*

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release, dated March 8, 2016, titled Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer.